What it is
Two different molecules are sold under the name CJC-1295, and the difference matters. Both are synthetic copies of the first 29 building blocks (amino acids) of growth-hormone-releasing hormone, or GHRH, the natural signal the brain sends to the pituitary gland to release growth hormone. Both have four of those building blocks swapped for different ones, which is why chemists call the base molecule "tetra-substituted GRF 1-29". The swaps slow down the enzymes in blood that would otherwise chop the peptide apart within minutes.
More on what it is and where it came from
The version the Canadian company ConjuChem developed carries one extra part: a 30th building block with a small reactive chemical cap called maleimidopropionamide attached to it. ConjuChem called this cap the Drug Affinity Complex, or DAC. After injection, the cap latches onto albumin, the most common protein in blood, and rides around attached to it. That is what stretches the drug's life in the body from minutes to about a week. In ConjuChem's own papers this albumin-binding molecule is simply "CJC-1295".
Products advertised as "CJC-1295 without DAC", "CJC-1295 no DAC" or "Modified GRF 1-29" are the base molecule without that cap. It is a different chemical with a different molecular weight, and it does not bind albumin, so it clears quickly. The US Food and Drug Administration (FDA) reviewed five related substances in 2024 and wrote that the naming is inconsistent across suppliers, scientific papers and public databases, that there are two genuinely different active molecules, and that this inconsistency is itself a safety risk because a person could receive a different substance from the one intended. FDA named the base molecule "CJC-1295 (free base)" and the albumin-binding one "CJC-1295 DAC (free base)". Neither is an approved medicine.
GHRH was isolated in 1982 and 1984 from tumours that were causing excess growth hormone, and chemists quickly found that only the first 29 amino acids were needed for activity. ConjuChem Biotechnologies of Montreal, Canada, set out to make that fragment last longer. In a 2005 paper in Endocrinology, Jetté and colleagues described attaching maleimide-based caps to the peptide so it would bond to the free sulphur atom on albumin, and identified the best of these as CJC-1295. Human trials in healthy volunteers followed in 2005 and 2006. ConjuChem then ran a phase 2 trial in people with HIV-associated fat redistribution; according to reports FDA later reviewed, that trial was stopped after a participant died, and the results were never published. Development did not resume. Two US compounding pharmacies later nominated CJC-1295 substances for pharmacy compounding, then withdrew the nominations; FDA evaluated them anyway and its advisory committee voted against all five forms in December 2024.
How it is thought to work
GHRH works by docking onto a receptor on the pituitary gland, which then releases growth hormone in pulses. Growth hormone in turn prompts the liver to make insulin-like growth factor 1 (IGF-1). A GHRH analogue is a laboratory-made copy of that signal. Because it pushes the body's own pituitary rather than supplying growth hormone directly, the pulses and the body's own brakes on them are preserved, at least in people whose pituitary still works.
More on how it works
In rat pituitary cells and in live rats, the albumin-bound version produced a larger and much longer growth hormone response than the unmodified 29-amino-acid fragment, and was still detectable in blood beyond 72 hours. In mice bred to make no GHRH of their own, a once-daily injection kept body weight, body length and body composition close to normal, while less frequent dosing did not. In healthy human volunteers, single injections raised growth hormone and IGF-1 for days.
Whether the uncapped "no DAC" molecule behaves the same way in people is not established. FDA searched the published literature in 2024 and reported that it could not find studies showing whether CJC-1295 free base or its acetate salt are pharmacologically active at all, and could not find any study in which either had been given to humans. The evidence that exists is for the albumin-binding version.
What is established in people
Everything known about CJC-1295 in people comes from three small studies in healthy volunteers, all of the albumin-binding (DAC) form, published between 2006 and 2009 and involving about 63 adults in total, most of whom received a single injection. They showed that the drug raises growth hormone and IGF-1 in blood for days to weeks and that the natural pulsing rhythm of growth hormone is preserved. They measured hormone levels, not health. No trial has shown that CJC-1295 builds muscle, reduces fat, heals injury, improves sleep or does anything else claimed for it. The one trial in patients, a phase 2 study in people with HIV-associated fat redistribution, was terminated and never published. For the molecule sold as "CJC-1295 without DAC" or "Modified GRF 1-29", FDA searched in 2024 and found no human study at all, and no study establishing that it is even pharmacologically active. No trial of CJC-1295 combined with ipamorelin was found on ClinicalTrials.gov; a search of that registry in November 2026 returned three ipamorelin studies, all of ipamorelin alone and none involving a GHRH analogue.
What the studies found
12 studies, human trials first. Each links to the paper or registry record.
- Human trial2009
Activation of the GH/IGF-1 axis by CJC-1295, a long-acting GHRH analog, results in serum protein profile changes in normal adult subjects
Using gel separation and mass spectrometry on blood serum, the authors found that two proteins (apolipoprotein A1 and transthyretin) decreased while fragments of albumin, a haemoglobin chain and an immunoglobulin fragment increased.
Full finding, who was studied, and limits
Who: Eleven healthy adult men, a subgroup of the participants in the Ionescu and Frohman study, sampled before and one week after a single injection.
Using gel separation and mass spectrometry on blood serum, the authors found that two proteins (apolipoprotein A1 and transthyretin) decreased while fragments of albumin, a haemoglobin chain and an immunoglobulin fragment increased. One spot tracked IGF-1 levels in a straight line, which the authors suggested could serve as a marker of growth hormone activity.
Read with care: Eleven men, one injection, no placebo arm. It looked for laboratory markers, not benefits. The paper did not discuss side effects at all.
- Human trial2006
Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults
A single injection raised average growth hormone in blood by two to ten times for six days or more, and IGF-1 by one and a half to three times for 9 to 11 days.
Full finding, who was studied, and limits
Who: Healthy adults aged 21 to 61 at two study sites, in two randomised, placebo-controlled, double-blind studies lasting 28 and 49 days. By FDA's reading of the paper, the first study had four escalating groups of six (five given the drug, one placebo) plus a further group of 18 (15 drug, 3 placebo), and the second study had 24 people in four groups of six. The substance was made by ConjuChem and was the albumin-binding (DAC) form.
A single injection raised average growth hormone in blood by two to ten times for six days or more, and IGF-1 by one and a half to three times for 9 to 11 days. The peptide's half-life was estimated at 5.8 to 8.1 days. With repeated injections the effect built up, and average IGF-1 stayed above its starting level for up to 28 days. Side effects were very common: in the first study, adverse events were recorded in 33 of 35 people given the drug (94%) against two of seven on placebo (29%).
Read with care: Small, short, and in healthy volunteers with a normal pituitary, not in patients with any disease. It measured hormone levels only. Nothing about muscle, fat, injury healing, sleep or any health outcome was measured. Most participants received only one or a few injections. Doses are recorded only in trialDoseNotes.
Journal of Clinical Endocrinology and Metabolism · pubmed.ncbi.nlm.nih.gov
- Human trial2006
Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog
The natural rhythm of growth hormone release was preserved: the number and size of the pulses did not change.
Full finding, who was studied, and limits
Who: Twelve healthy men aged 20 to 40. Each had blood taken every 20 minutes through a 12-hour overnight period before the injection and again a week after it. Same experimental substance as the Teichman study.
The natural rhythm of growth hormone release was preserved: the number and size of the pulses did not change. What rose sharply was the baseline between pulses, which went up about 7.5-fold (P less than 0.0001). Average growth hormone rose 46% (P less than 0.01) and IGF-1 rose about 44% a week after the injection (P less than 0.001). IGF-1 stayed inside the normal range in every participant.
Read with care: Twelve healthy young men, one injection each, no placebo group, one week of follow-up. It is a hormone-measuring study, not a test of any benefit or of safety beyond a week.
Journal of Clinical Endocrinology and Metabolism · pubmed.ncbi.nlm.nih.gov
- Human trial2006
A multicenter, randomized, placebo-controlled, double-blind Phase 2 study of CJC 1295 given for 12 weeks to HIV-infected patients with HIV-associated visceral obesity (NCT00267527)
The trial was terminated and no results were ever posted or published.
Full finding, who was studied, and limits
Who: Adults with HIV and HIV-associated fat redistribution, randomised to a lower-dose arm, a higher-dose arm or placebo, with weekly injections planned for 12 weeks. The registry lists 120 participants; the reports FDA reviewed say 192 were enrolled and randomised. The registry record was last updated in October 2006.
The trial was terminated and no results were ever posted or published. According to reports FDA summarised in 2024, about two hours after an eleventh weekly injection one participant complained of chest discomfort, an electrocardiogram confirmed a heart attack, and the person died roughly an hour later. The attending physician's stated most likely explanation was that the participant had symptomless coronary artery disease and that a plaque in an artery ruptured and blocked it. Causation by the drug was not established, and no information about the other participants or their side effects was available.
Read with care: This is the only trial of CJC-1295 in people with a medical condition, and its data have never been published, so nothing can be concluded from it about whether the drug worked. The account of the death is second-hand: FDA labelled its sources as anecdotal internet reports and no clinical report or inquest finding was located. A single death in a group of this size cannot show that a drug caused it, and equally cannot rule it out. The registry and the reports disagree on how many people were enrolled.
ClinicalTrials.gov, sponsored by ConjuChem · clinicaltrials.gov
- Review2026
Peptide Supplements and Their Therapeutic Applications in Sports Medicine
Sixty-seven per cent of the publications found were animal studies, mostly in rats.
Full finding, who was studied, and limits
Who: A scoping review by orthopaedic surgeons at UCLA, following PRISMA method, covering six peptides sold for recovery and performance: BPC-157, thymosin beta-4 (TB-500), CJC-1295, MK-677, ipamorelin and GHK-Cu.
Sixty-seven per cent of the publications found were animal studies, mostly in rats. Human studies were few and mostly lacked proper controls. The authors concluded that human trials do not support the claimed benefits for musculoskeletal recovery or performance, that documented risks include heart problems and insulin resistance, and that these peptides should not currently be recommended in place of or alongside standard orthopaedic care.
Read with care: A scoping review, which maps what exists rather than pooling results. It covers six peptides together and its abstract gives no finding specific to CJC-1295.
The American Journal of Sports Medicine · pubmed.ncbi.nlm.nih.gov
- Review2024
FDA Evaluation of CJC-1295 Related Bulk Drug Substances (CJC-1295 free base, CJC-1295 acetate, CJC-1295 with drug affinity complex (DAC) free base, CJC-1295 DAC acetate, and CJC-1295 DAC trifluoroacetate)
FDA concluded that the evidence weighs against allowing any of the five substances to be used in pharmacy compounding.
Full finding, who was studied, and limits
Who: An FDA review of all publicly available chemistry, animal and human data on five CJC-1295 substances, assessed for use in growth hormone deficiency.
FDA concluded that the evidence weighs against allowing any of the five substances to be used in pharmacy compounding. Its findings: none is a component of an approved drug and none has a pharmacopoeia standard; the naming across suppliers, papers and databases is inconsistent enough to be a safety risk in itself; the certificates of analysis FDA could find did not test for impurities, clumped peptide or bacterial toxins; the peptide is 86% identical to the body's own GHRH, so an immune reaction against it could in principle also attack the natural hormone; and there are no studies at all of effectiveness in people with growth hormone deficiency. FDA found no published study of any kind in which CJC-1295 free base or its acetate salt had been given to humans, and no study establishing that either is pharmacologically active.
Read with care: This is a regulatory review of compounding, written for one proposed use, not a systematic review of the science. It reflects what was publicly available in late 2024.
- Animal study2020
DNA damage and growth hormone hypersecretion in pituitary somatotroph adenomas (Ben-Shlomo et al. 2020), as summarised by FDA
In the cultured pituitary cells, CJC-1295 DAC increased growth hormone release in step with concentration, and caused measurable DNA damage along with a marker of the DNA damage response.
Full finding, who was studied, and limits
Who: Cultured mouse pituitary cells and four-month-old mice treated for eight weeks.
In the cultured pituitary cells, CJC-1295 DAC increased growth hormone release in step with concentration, and caused measurable DNA damage along with a marker of the DNA damage response. In the live mice, eight weeks of treatment enlarged the front part of the pituitary gland, caused DNA damage in it and raised the same marker. FDA also pointed to older work showing that mice engineered to overproduce human GHRH develop pituitary overgrowth and tumours, and said the possibility that long-term use causes the same thing cannot be ruled out without cancer studies, which do not exist.
Read with care: Mouse cells and mice, not people. It is a mechanism signal, not evidence that anyone has been harmed. No human data exist either way.
Journal of Clinical Investigation; summarised in FDA's 2024 briefing document · fda.gov
- Animal study2016
Qualitative identification of growth hormone-releasing hormones in human plasma by means of immunoaffinity purification and LC-HRMS/MS
The authors treat CJC-1295, CJC-1293, sermorelin and tesamorelin together as GHRH analogues that are prohibited in sport at all times.
Full finding, who was studied, and limits
Who: Rats given four GHRH analogues, plus three blood samples from one human volunteer given sermorelin. A doping-control method development study from the Cologne laboratory.
The authors treat CJC-1295, CJC-1293, sermorelin and tesamorelin together as GHRH analogues that are prohibited in sport at all times. CJC-1295 remained detectable intact in rat blood up to eight hours after dosing with no breakdown products seen, which the authors attribute to the D-alanine substitution at position 2. Sermorelin, by contrast, was completely destroyed in human blood within four hours in the laboratory and could not be detected intact in the volunteer at all.
Read with care: A detection-method paper. It measured no health effect. The eight-hour rat sampling window does not speak to the week-long action of the albumin-binding form in people.
Analytical and Bioanalytical Chemistry (PMC4830873) · pmc.ncbi.nlm.nih.gov
- Animal study2006
Once-daily administration of CJC-1295, a long-acting growth hormone-releasing hormone (GHRH) analog, normalizes growth in the GHRH knockout mouse
Injected once a day, CJC-1295 kept the mice's body weight, body length and body composition normal.
Full finding, who was studied, and limits
Who: Mice genetically engineered to make no GHRH of their own. The abstract does not give group sizes.
Injected once a day, CJC-1295 kept the mice's body weight, body length and body composition normal. Giving it every second or third day did not restore growth as completely. Treatment also increased the pituitary's growth hormone messenger RNA, which the authors read as the hormone-producing cells multiplying.
Read with care: Mice that make no GHRH at all are a special case and not a model of an ordinary adult. It measured growth and hormone signals, not safety or any outcome in people.
American Journal of Physiology - Endocrinology and Metabolism · pubmed.ncbi.nlm.nih.gov
- Animal study2006
Nonclinical toxicity studies of CJC-1295 DAC in rats, dogs and monkeys (Iordanova et al. 2004, 2005, 2006; Wen et al. 2005), as summarised by FDA
Repeated injections in rats and dogs consistently caused bleeding, inflammation and tissue death at the injection site.
Full finding, who was studied, and limits
Who: Sprague-Dawley and CD rats given single or repeated injections, Beagle dogs given single or repeated injections for up to 14 days, pregnant rats (25 per group) dosed during pregnancy, and cynomolgus monkeys given repeated injections over six months.
Repeated injections in rats and dogs consistently caused bleeding, inflammation and tissue death at the injection site. Rats also showed less food and water intake, loose stools, reduced activity, lower red blood cell counts, haemoglobin and haematocrit (down 5 to 15%), and heavier livers. Dogs showed reduced activity, vomiting, injection-site irritation, lower haemoglobin and red-cell mass (down about 16%) and higher cholesterol. In pregnant rats there were no effects on the survival or appearance of the offspring. In monkeys the authors reported no immune or immunotoxic effects, though FDA noted the description was vague.
Read with care: All of these exist only as conference abstracts, which are not peer-reviewed papers and give few details. All used an unspecified form of the DAC molecule. FDA noted that no acute or repeat-dose toxicity study of any kind was found for the uncapped molecule sold as "no DAC". There is no two-year cancer study for any form.
- Animal study2005
Human growth hormone-releasing factor (hGRF)1-29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats: identification of CJC-1295 as a long-lasting GRF analog
The authors made three versions of the 29-amino-acid GHRH fragment with reactive caps that bond to albumin, and tested them.
Full finding, who was studied, and limits
Who: Cultured rat pituitary cells and male Sprague-Dawley rats, by researchers at ConjuChem. The abstract does not give the number of animals.
The authors made three versions of the 29-amino-acid GHRH fragment with reactive caps that bond to albumin, and tested them. All three resisted the enzyme that normally destroys GHRH and made cultured pituitary cells release growth hormone. The best of the three, which the authors named CJC-1295, produced about four times the growth hormone response of the plain fragment over two hours in rats and was still present in blood beyond 72 hours. Laboratory testing showed the peptide attached to the albumin band within 15 minutes and still attached beyond 24 hours. This is the paper that defines CJC-1295 as the tetra-substituted fragment plus the albumin-binding cap.
Read with care: Rats and rat cells. It measured hormone release, not any health outcome. It tells you nothing about the uncapped molecule sold as "no DAC".
- Cell study2010
Identification of CJC-1295, a growth-hormone-releasing peptide, in an unknown pharmaceutical preparation
Using liquid chromatography with high-resolution mass spectrometry, the laboratory found a 29-amino-acid peptide with an amide on its tail end and worked out a sequence from the data.
Full finding, who was studied, and limits
Who: Not a study in cells or animals: a laboratory analysis of an unidentified preparation seized by Norwegian authorities, carried out by the Oslo doping control laboratory.
Using liquid chromatography with high-resolution mass spectrometry, the laboratory found a 29-amino-acid peptide with an amide on its tail end and worked out a sequence from the data. The authors stated the sequence was consistent with a peptide then being marketed under the name CJC-1295. They noted that the substance is prohibited in sport under section S2 of the WADA list, that it was readily available, and that it was likely being used in bodybuilding.
Read with care: One product, analysed in 2009, identified by interpreting mass spectra rather than against a reference standard. A 29-amino-acid chain with no 30th lysine is the uncapped molecule, but the abstract does not spell that out. It cannot tell you what any product on sale today contains.
Safety findings
- Side effects were very common in the healthy-volunteer trials, though none was serious. In the first Teichman study, adverse events occurred in 33 of 35 people given the drug (94%) against two of seven on placebo (29%). Injection-site reactions affected about 70%; hives at the injection site about 30%; headache 63% against 14% on placebo; diarrhoea 43%; and flushing, warmth and transient low blood pressure 30%. In the second study, injection-site reactions occurred in everyone given the drug, flushing within 30 minutes of injection in 40% to 100% depending on the group, and two people had brief dizziness and low blood pressure after a first injection. Most effects were worse at higher doses. Source: fda.gov
- In the Ionescu and Frohman study, the reported side effects were a rise in heart rate that tracked the dose, and transient redness and tenderness at the injection site. No serious adverse events were reported. Source: fda.gov
- FDA's bulk-substances page states, as its stated reason for the substance appearing there: "FDA has identified serious adverse events associated with CJC-1295 including increased heart rate and systemic vasodilatory reaction." The same entry says compounded products may pose a risk of immune reaction for some routes of administration, may be complicated by peptide-related impurities and difficulty characterising the ingredient, and that available clinical data are limited. Source: fda.gov
- One death occurred in the only trial in patients. In ConjuChem's phase 2 study in HIV-associated fat redistribution, a participant had a heart attack about two hours after an eleventh weekly injection and died roughly an hour later. The attending physician's stated most likely explanation was pre-existing symptomless coronary artery disease with rupture and blockage of an artery. Causation by the drug was not established. The trial was terminated and the data were never published. Source: fda.gov
3 more safety findings
- No long-term human safety data exist for either molecule. FDA noted that the available studies were in healthy adults, were small, and were short, even though the substance was nominated to treat a lifelong condition, and that there is no safety information at all for use in children. FDA searched its adverse event database (FAERS) to June 2024 and found two reports, both excluded for lack of usable information, and found no reports in the food and supplement database. Source: fda.gov
- FDA's main chemical concern is immunogenicity: an immune reaction to the injected peptide, made more likely by clumping of the peptide and by impurities left over from manufacture. Because CJC-1295 is 86% identical to the body's own GHRH, FDA warned that antibodies raised against it could cross-react with the natural hormone. Source: fda.gov
- Animal signals that have no human counterpart yet: repeated injections caused bleeding, inflammation and tissue death at the injection site in rats and dogs; the drug caused DNA damage in mouse pituitary cells and in mouse pituitary glands; and no cancer study has ever been done, so the possibility of pituitary overgrowth with long-term use is unresolved. Source: fda.gov
Rules and status
Not approved for any use, in any form. CJC-1295 is not on the list of bulk substances that pharmacies may lawfully compound with, and in December 2024 FDA's advisory committee voted against adding any of its five forms to that list.
The full history, with dates
What is formally established: (1) No approval. FDA's November 2024 review states that none of the five CJC-1295 substances is a component of any FDA-approved drug and that no pharmacopoeia standard exists for any of them. (2) Nominations withdrawn, reviewed anyway. Two compounding pharmacies (Wells Pharmacy Network and LTD Health Solutions) nominated CJC-1295 substances for the 503A bulk drug substances list, then withdrew the nominations. FDA chose to evaluate them anyway and proposed not adding any of them. (3) Advisory committee vote. At the Pharmacy Compounding Advisory Committee meeting of 4 December 2024, the committee first voted 12 to 1 to consider the five substances as a group, then, because that was not unanimous, voted on each separately. Every one was rejected: CJC-1295 free base 0 yes to 13 no, CJC-1295 acetate 1 yes to 12 no, CJC-1295 DAC free base 0 to 13, CJC-1295 DAC acetate 0 to 13, CJC-1295 DAC trifluoroacetate 0 to 13. The minutes record that the committee unanimously agreed CJC-1295 free base should not be on the list and that one member commented on the lack of evidence of effectiveness. The minutes were approved on 21 February 2025. (4) Current list position. FDA's page on bulk substances that may present significant safety risks, content current as of 22 April 2026, lists CJC-1295 in its table of substances "nominated but withdrawn", with the stated reasons quoted in the safety section above. FDA's category list, updated 14 May 2026, shows CJC-1295 in none of the three categories. (5) HHS enforcement policy of 30 October 2026. The Department of Health and Human Services published a Federal Register notice (91 FR 68526) announcing a draft, non-binding policy under which it would not take enforcement action against pharmacies, federal facilities or physicians compounding with certain peptides listed in an appendix, while rulemaking proceeds. The notice itself names no peptides. Appendix A of the policy (on hhs.gov, read from an Internet Archive capture of 15 November 2026) names exactly six peptides: BPC-157, epitalon, KPV, MOTS-c, semax and TB-500. CJC-1295 is not among them. No proposed or final rule adding CJC-1295 to the compounding list was found. None of this changes the fact that CJC-1295 is an unapproved drug and that products sold online are not made under any pharmaceutical quality standard.
Source: fda.gov (source dated 2026-04-22)
In sport: Prohibited at all times, in and out of competition. CJC-1295 is named in class S2 (Peptide hormones, growth factors, related substances, and mimetics), section S2.2.4 'Growth hormone releasing factors', in the line 'growth hormone-releasing hormone (GHRH) and its analogues (e.g. CJC-1293, CJC-1295, sermorelin and tesamorelin)'. The wording is the same in the 2026 List (in force from 1 January 2026) and the 2027 List (published 21 September 2026, in force from 1 January 2027). The 2026 List states that all substances in S2 are non-Specified Substances. WADA
Claims and what the evidence supports
| What people say | What the evidence supports |
|---|---|
| CJC-1295 and "CJC-1295 no DAC" are the same thing, one just lasts longer. | They are different molecules with different molecular formulas and weights. The DAC version carries an extra amino acid and a chemical cap that bonds to albumin in the blood. FDA treats them as two distinct active substances that are not interchangeable, and says the inconsistent naming is itself a safety risk because a person may receive a different substance from the one intended. Source: fda.gov |
| "CJC-1295 no DAC" (Modified GRF 1-29) is well studied. | FDA searched the published literature in 2024 and found no study in which CJC-1295 free base or its acetate salt had been given to humans, no study establishing that either is pharmacologically active, and no animal toxicity study of any kind for them. Source: fda.gov |
| Clinical trials proved CJC-1295 works. | Three published studies in healthy volunteers measured growth hormone and IGF-1 in blood. They did not measure muscle, fat, strength, recovery, sleep or any health outcome. FDA concluded there are no data on effectiveness for any CJC-1295 substance for the condition it was nominated to treat. Source: pubmed.ncbi.nlm.nih.gov |
| It is safe because trials reported no serious side effects. | Serious adverse events were not reported in the volunteer studies, but ordinary ones were near-universal: injection-site reactions in about 70% to 100% of participants, headache in 63% against 14% on placebo, and flushing with transient low blood pressure in 30%. Most participants received a single injection and the longest study ran 49 days. FDA's own page lists increased heart rate and systemic vasodilatory reaction as serious adverse events it has identified. Source: fda.gov |
| Development stopped for business reasons, not safety. | The phase 2 trial in HIV-associated fat redistribution was terminated after a participant died of a heart attack hours after an injection. The attending physician attributed it to pre-existing symptomless coronary artery disease and causation by the drug was never established, but the trial stopped, the data were never published, and development did not resume. FDA records the account as anecdotal because no formal report was published. Source: fda.gov |
| CJC-1295 plus ipamorelin is a proven combination. | No trial of the two together was found. A search of ClinicalTrials.gov in November 2026 returned three ipamorelin studies, both completed ones testing ipamorelin alone for recovery of bowel function after surgery, and none involving a GHRH analogue. FDA's 2024 review discusses CJC-1295 alone and identifies no combination study. Source: clinicaltrials.gov |
| Because it makes your own body release growth hormone, it avoids the risks of growth hormone itself. | Growth hormone and IGF-1 did rise in the volunteer studies, which is the point. FDA stated that it found nothing to suggest these substances would not carry the same risks listed on the labels of approved growth hormone products, which include increased risk of new growths, glucose intolerance, fluid retention and raised pressure inside the skull. Mice engineered to overproduce GHRH develop pituitary overgrowth and tumours, and no cancer study of CJC-1295 has ever been done. Source: fda.gov |
| It is a legal research chemical, so quality is not a concern. | FDA examined publicly available certificates of analysis and found they did not test for impurities, clumped peptide or bacterial toxins, and that one certificate gave a chemical name that did not match any known CJC-1295 substance. Separately, a doping laboratory that analysed a seized product in 2009 could only say its sequence was "consistent with" the marketed name. Source: fda.gov |
What a genuine lab report should show
- The report must say which molecule was tested. "CJC-1295" alone is not enough. It should state either the 29-amino-acid tetra-substituted peptide (no DAC) or the 30-amino-acid version carrying the maleimidopropionamide cap, because both are sold under the same name.
- Identity by mass spectrometry should match the right molecular weight: about 3367.95 g/mol for the version without DAC, or about 3647.95 g/mol for the version with DAC. A measured mass near one figure on a vial labelled as the other means the label is wrong. FDA found a supplier certificate on which the chemical name, formula and weight described the no-DAC molecule while the product was named as something else.
- It should state whether the material is the free base or a salt, and which salt. FDA treats the free base, the acetate and the trifluoroacetate as different substances, and found suppliers reusing the same CAS number across different forms (one of which, 863288-34-0, is a deleted CAS number).
- Purity by HPLC with the percentage of the largest single impurity and of total impurities, not only a headline purity figure. FDA pointed out that a certificate showing 99.0% purity against a 98.0% limit still says nothing about what the remaining 2% is.
- Because this is an injectable peptide, a full report would also show the amount of peptide actually present (assay or net peptide content), a bacterial endotoxin test, a bioburden test, and a test for aggregates (clumped peptide). FDA flagged the absence of all of these on the certificates it found, and aggregation is its main stated immunogenicity concern.
- A lot or batch number matching the vial, the name of the testing laboratory, and the test date, so the report can be traced to the product in hand.
What is not known
- Whether the molecule sold as "CJC-1295 without DAC" or "Modified GRF 1-29" does anything in a person. FDA found no human study and no evidence that it is pharmacologically active. It is assumed to behave like a short-acting GHRH analogue, but that has not been demonstrated for this exact molecule.
- What a product labelled CJC-1295 actually contains. Only one published analysis of a seized product was found, from 2009, and it identified a 29-amino-acid peptide by interpreting mass spectra rather than against a reference standard. No survey of products currently on sale was found.
- What really happened in the ConjuChem phase 2 trial. The data have never been published, the registry record has no reason for termination, and FDA's account of the participant's death rests on two internet reports from 2006 that FDA itself calls anecdotal. The registry says 120 participants and those reports say 192.
- Whether the serious adverse events FDA refers to on its bulk-substances page (increased heart rate and systemic vasodilatory reaction) are the same events described in the published volunteer studies or separate reports. FDA does not say.
- Whether taking CJC-1295 with ipamorelin, as it is commonly sold, behaves differently from taking either alone. No trial of the combination was found in people or, in the sources opened here, in animals.
- Long-term safety, including whether repeatedly stimulating the pituitary raises the risk of pituitary overgrowth or tumours. Mouse data raise the question; no cancer study and no human data of any length exist to answer it. The longest controlled human exposure found was 49 days.
Sources
All 29 sources
- FDA Evaluation of CJC-1295 Related Bulk Drug Substances, briefing document dated 15 November 2024 for the 4 December 2024 Pharmacy Compounding Advisory Committee meeting. fda.gov
- FDA introductory briefing document for the 4 December 2024 Pharmacy Compounding Advisory Committee meeting. fda.gov
- FDA Final Summary Minutes of the Pharmacy Compounding Advisory Committee meeting, 4 December 2024 (approved 21 February 2025), with the vote tallies on all five CJC-1295 substances. fda.gov
- FDA advisory committee calendar page for the 4 December 2024 Pharmacy Compounding Advisory Committee meeting. fda.gov
- FDA: Certain bulk drug substances for use in compounding that may present significant safety risks (content current as of 22 April 2026); CJC-1295 appears in the "nominated but withdrawn" table. fda.gov
- FDA: Bulk drug substances nominated for use in compounding under section 503A, category list (updated 14 May 2026); CJC-1295 appears in none of the three categories. fda.gov
- Federal Register, 30 October 2026 (91 FR 68526): HHS notice of availability, Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances. govinfo.gov
- HHS Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances, with Appendix A (the six peptides) and Appendix B (HHS reasoning); read from an Internet Archive capture of 15 November 2026. hhs.gov
- Federal Register, 4 March 2013: FDA determination that GEREF (sermorelin acetate), NDA 019863 and NDA 020443, was not withdrawn for reasons of safety or effectiveness; approval of both was withdrawn effective 18 June 2009. govinfo.gov
- FDA label for EGRIFTA (tesamorelin for injection), a growth hormone releasing factor analogue approved in 2010 for reduction of excess abdominal fat in HIV-infected patients with lipodystrophy. accessdata.fda.gov
- PubChem CID 91971820: CJC-1295 with DAC (C165H269N47O46, CAS 446262-90-4). pubchem.ncbi.nlm.nih.gov
- PubChem CID 91976842: listed as "CJC1295 Without DAC" (C152H252N44O42). pubchem.ncbi.nlm.nih.gov
- PubChem CID 56841945: a record carrying the no-DAC formula but mixing "with DAC" and "no DAC" synonyms, and the deleted CAS 863288-34-0. pubchem.ncbi.nlm.nih.gov
- Jetté et al. 2005: identification of CJC-1295 as a long-lasting GRF analogue (rats). pubmed.ncbi.nlm.nih.gov
- Alba et al. 2006: once-daily CJC-1295 normalises growth in the GHRH knockout mouse. pubmed.ncbi.nlm.nih.gov
- Teichman et al. 2006: prolonged stimulation of GH and IGF-1 by CJC-1295 in healthy adults (phase 1). pubmed.ncbi.nlm.nih.gov
- Ionescu and Frohman 2006: GH pulsatility persists during continuous stimulation by CJC-1295 (12 healthy men). pubmed.ncbi.nlm.nih.gov
- Sackmann-Sala et al. 2009: serum protein profile changes after CJC-1295 in 11 healthy men. pubmed.ncbi.nlm.nih.gov
- ClinicalTrials.gov NCT00267527: ConjuChem phase 2 of CJC-1295 in HIV-associated visceral obesity (terminated, no results posted). clinicaltrials.gov
- Henninge et al. 2010: identification of CJC-1295 in an unknown pharmaceutical preparation seized in Norway. pubmed.ncbi.nlm.nih.gov
- Knoop et al. 2016: identification of GHRH analogues including CJC-1295, sermorelin and tesamorelin in plasma for doping control. pmc.ncbi.nlm.nih.gov
- Fabresse et al. 2017: identification of the GHRH peptide analogue CJC-1295 using LC-HRMS/MS (cited by FDA; not opened for this page). pubmed.ncbi.nlm.nih.gov
- Gajda et al. 2019: glycine-modified growth hormone secretagogues, including modified GRF 1-29, in seized doping material. pubmed.ncbi.nlm.nih.gov
- Sigalos and Pastuszak 2018: the safety and efficacy of growth hormone secretagogues (review). pubmed.ncbi.nlm.nih.gov
- Tewari et al. 2026: peptide supplements and their therapeutic applications in sports medicine (scoping review covering CJC-1295). pubmed.ncbi.nlm.nih.gov
- Detection of CJC-1295 in equine plasma by ELISA, 2026. pubmed.ncbi.nlm.nih.gov
- ClinicalTrials.gov NCT01280344: ipamorelin alone for recovery of gastrointestinal function (one of only three ipamorelin studies in the registry; none combines it with CJC-1295). clinicaltrials.gov
- WADA 2026 Prohibited List (in force 1 January 2026). wada-ama.org
- WADA 2027 Prohibited List, published 21 September 2026, in force 1 January 2027. wada-ama.org
Sources last checked 2026-11-18.
This page summarises published research and public records for education. It is not medical advice and it is not a guide to using any compound. If something here is wrong or out of date, tell us and we will correct it.